Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

v3.19.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
9 Months Ended
Jul. 31, 2019
Jul. 31, 2018
Cash flows from operating activities:    
Net loss $ (9,707,591) $ (8,851,564)
Stock option compensation to employees and directors 2,808,910 3,598,986
Stock options and warrants issued to consultants 139,161 254,090
Restricted stock award compensation to employee pursuant to stock incentive plan 1,954,441 1,373,940
Common stock issued to consultants 15,002
Depreciation of property and equipment 32,990 12,414
Amortization of patents 418,750 243,972
Impairment in carrying amount of patent assets 418,750
Issuance of noncontrolling interest in Certainty Therapeutics, Inc. expensed as a license fee 64,656
Change in operating assets and liabilities:    
Receivables 305,919 (40,710)
Prepaid expenses and other current assets 45,847 (163,211)
Accounts payable (14,234) (60,914)
Accrued expenses 192,672 300,888
Net cash used in operating activities (3,404,385) (3,252,451)
Cash flows from investing activities:    
Disbursements to acquire short-term investments in certificates of deposit (2,350,000) (4,000,000)
Proceeds from maturities of short-term investments in certificates of deposit 2,250,000 4,750,000
Purchase of property and equipment (175,457) (31,853)
Net cash (used in) provided by investing activities (275,457) 718,147
Cash flows from financing activities:    
Net proceeds from sale of common stock in at-the-market offering 4,899,745 1,786,029
Proceeds from sale of common stock pursuant to employee stock purchase plan 18,560
Proceeds from exercise of employee stock options 102,500
Net cash provided by financing activities 5,020,805 1,786,029
Net increase (decrease) in cash and cash equivalents 1,340,963 (748,275)
Cash and cash equivalents at beginning of period 3,055,890 3,339,374
Cash and cash equivalents at end of period $ 4,396,853 $ 2,591,099